Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a continuous glucose monitor (CGM) to market. Dublin, Ireland-based Trinity Biotech appointed Barclays as its exclusive financial advisor to support an ongoing strategic realignment. The company aims to increase its focus on its “disruptive” CGM technology as part […]
Trinity Biotech
Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
Trinity Biotech (Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system. Dublin, Ireland-based Trinity’s trial included 30 participants, primarily with type 1 diabetes. The company said it represents a significant milestone in its mission to deliver high-performance CGM technology. Its study highlighted the system’s signal quality, accuracy and more. The […]
Trinity Biotech completes pre-pivotal study of next-gen CGM
Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM technology. The study assessed the analytical performance of continuous glucose monitoring (CGM) technology enhancements implemented by Trinity. Dublin, Ireland-based Trinity added the improvements to the CGM technology it acquired from Waveform Technologies in January. Trinity implemented an […]
